Bone Biologics summarizes key milestones achieved during 2025

Bone Biologics (BBLG) summarized key corporate, scientific, and operational milestones achieved during 2025 and outlined its strategic outlook for 2026. 2025 Highlights: Extended rhNELL-1 Product Shelf Life; SCompleted a registered public offering for total gross proceeds of $5 million during the second quarter of 2025; filed a U.S. patent application related to its bone regeneration technology based on recombinant human NELL-1; regained compliance with Nasdaq’s minimum bid price requirement. Outlook for 2026: Clinical Development Progression – Continuing advancement of NB1, the Company’s rhNELL-1-based bone graft product candidate, including the expected completion of patient enrollment in its first-in-human clinical trial and potential interim updates, as appropriate; Operational and Manufacturing Execution – Ongoing efforts to support regulatory readiness and future commercialization planning; Intellectual Property Strategy – Continuing pursuit of relevant patent protections to enhance long-term platform value; Financial Discipline and Strategic Focus – Maintaining prudent capital management while supporting scientific progress and shareholder engagement.